Viltepso (Viltolarsen) (for Pennsylvania Only)
UnitedHealthcare Medical Benefit Drug Policy for Viltepso (viltolarsen) applies only to Pennsylvania and describes criteria for initial and continuation coverage for treatment of Duchenne muscular dystrophy (DMD) amenable to exon 53 skipping, coding references, background, evidence, and FDA indication.
Revised coverage criteria for initial therapy to add requirement that one of the following be met: patient has not previously received gene therapy for DMD; or both prior gene therapy and documentation of clinically meaningful functional decline since gene therapy.
Coverage Summary
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.